| Year |
Citation |
Score |
| 2023 |
Vile R, Webb M, van Vloten J, Evgin L, Sangsuwannukul T, Kendall B, Tonne J, Thompson J, Metko M, Moore M, Yerovi MC, McNiven M, Monga S, Borad M, Roberts L. Chimerization of the Anti-Viral CD8+ T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic Virotherapy. Research Square. PMID 38045348 DOI: 10.21203/rs.3.rs-3576281/v1 |
0.452 |
|
| 2023 |
Smith KER, Peng KW, Pulido JS, Weisbrod AJ, Strand CA, Allred JB, Newsom AN, Zhang L, Packiriswamy N, Kottke T, Tonne JM, Moore M, Montane HN, Kottschade LA, McWilliams RR, ... ... Vile RG, et al. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses. Frontiers in Immunology. 14: 1279387. PMID 38022659 DOI: 10.3389/fimmu.2023.1279387 |
0.333 |
|
| 2023 |
Webb MJ, Sener U, Vile RG. Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma. Pharmaceuticals (Basel, Switzerland). 16. PMID 37375742 DOI: 10.3390/ph16060793 |
0.428 |
|
| 2023 |
Webb MJ, Kottke T, Kendall BL, Swanson J, Uzendu C, Tonne J, Thompson J, Metko M, Moore M, Borad M, Roberts L, Diaz RM, Olin M, Borgatti A, Vile R. Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses. Molecular Therapy Oncolytics. 29: 129-142. PMID 37313455 DOI: 10.1016/j.omto.2023.05.006 |
0.518 |
|
| 2023 |
Tritz ZP, Ayasoufi K, Wolf DM, Owens CA, Malo CS, Himes BT, Fain CE, Goddery EN, Yokanovich LT, Jin F, Hansen MJ, Parney IF, Wang C, Moynihan KD, Irvine DJ, ... ... Vile RG, et al. Anti-PD-1 and extended half-life-IL-2 synergize for treatment of murine glioblastoma independent of host MHC Class I expression. Cancer Immunology Research. PMID 36921098 DOI: 10.1158/2326-6066.CIR-22-0570 |
0.397 |
|
| 2022 |
Nagalo BM, Zhou Y, Loeuillard EJ, Dumbauld C, Barro O, Elliott NM, Baker AT, Arora M, Bogenberger JM, Meurice N, Petit J, Uson Junior PLS, Aslam F, Raupach E, Gabere M, ... ... Vile R, et al. Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers. Hepatology (Baltimore, Md.). PMID 36052732 DOI: 10.1002/hep.32769 |
0.439 |
|
| 2022 |
Schuelke MR, Gundelach JH, Coffey M, West E, Scott K, Johnson DR, Samson A, Melcher A, Vile RG, Bram RJ. Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors. Neuro-Oncology Advances. 4: vdac085. PMID 35821679 DOI: 10.1093/noajnl/vdac085 |
0.313 |
|
| 2022 |
Samson A, West EJ, Carmichael J, Scott KJ, Turnbull S, Kuszlewicz B, Dave RV, Peckham-Cooper A, Tidswell E, Kingston J, Johnpulle M, Da Silva BL, Jennings VA, Bendjama K, Stojkowitz N, ... ... Vile RG, et al. Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anti-Cancer Immunity in Patients. Cancer Immunology Research. PMID 35439304 DOI: 10.1158/2326-6066.CIR-21-0171 |
0.389 |
|
| 2022 |
Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, Moore M, Michael J, Driscoll C, Pulido J, Swanson E, Kennedy R, Coffey M, Loghmani H, Sanchez-Perez L, ... ... Vile RG, et al. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Science Translational Medicine. 14: eabn2231. PMID 35417192 DOI: 10.1126/scitranslmed.abn2231 |
0.484 |
|
| 2022 |
Bozhanova G, Hassan J, Appleton L, Jennings V, Foo S, McLaughlin M, Chan Wah Hak CM, Patin EC, Crespo-Rodriguez E, Baker G, Armstrong E, Chiu M, Pandha H, Samson A, Roulstone V, ... ... Vile R, et al. CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma. Journal For Immunotherapy of Cancer. 10. PMID 35338089 DOI: 10.1136/jitc-2021-004410 |
0.36 |
|
| 2022 |
Zamanian C, Bhandarkar AR, Monie DD, Moinuddin FM, Vile RG, Quiñones-Hinojosa A, Bydon M. Systems neuroimmunology: a review of multiomics methodologies to characterize neuroimmunological interactions in spinal and cranial diseases. Neurosurgical Focus. 52: E9. PMID 35104798 DOI: 10.3171/2021.11.FOCUS21571 |
0.725 |
|
| 2021 |
Monie DD, Correia C, Zhang C, Ung CY, Vile RG, Li H. Modular network mechanism of CCN1-associated resistance to HSV-1-derived oncolytic immunovirotherapies for glioblastomas. Scientific Reports. 11: 11198. PMID 34045642 DOI: 10.1038/s41598-021-90718-1 |
0.777 |
|
| 2021 |
Evgin L, Vile RG. Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals? Cancers. 13. PMID 33807553 DOI: 10.3390/cancers13051106 |
0.373 |
|
| 2021 |
Kottke T, Tonne J, Evgin L, Driscoll CB, van Vloten J, Jennings VA, Huff AL, Zell B, Thompson JM, Wongthida P, Pulido J, Schuelke MR, Samson A, Selby P, Ilett E, ... ... Vile RG, et al. Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nature Communications. 12: 1930. PMID 33772027 DOI: 10.1038/s41467-021-22115-1 |
0.78 |
|
| 2021 |
Annels NE, Simpson GR, Denyer M, Arif M, Coffey M, Melcher A, Harrington K, Vile R, Pandha H. Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors. Molecular Therapy Oncolytics. 20: 434-446. PMID 33665363 DOI: 10.1016/j.omto.2020.09.010 |
0.312 |
|
| 2021 |
Vile RG, Melcher A, Pandha H, Harrington KJ, Pulido JS. APOBEC and cancer viroimmunotherapy: Thinking the Unthinkable. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33558423 DOI: 10.1158/1078-0432.CCR-20-1888 |
0.407 |
|
| 2021 |
Monie DD, Bhandarkar AR, Parney IF, Correia C, Sarkaria JN, Vile RG, Li H. Synthetic and systems biology principles in the design of programmable oncolytic virus immunotherapies for glioblastoma. Neurosurgical Focus. 50: E10. PMID 33524942 DOI: 10.3171/2020.12.FOCUS20855 |
0.767 |
|
| 2020 |
Huff AL, Evgin L, Thompson J, Kottke T, Driscoll CB, Tonne J, Wongthida P, Schuelke M, Shim KG, Mer G, Ramirez-Alvarado M, Vile R. Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell Responses. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 32877695 DOI: 10.1016/J.Ymthe.2020.08.013 |
0.793 |
|
| 2020 |
Crespo-Rodriguez E, Bergerhoff K, Bozhanova G, Foo S, Patin EC, Whittock H, Buus R, Haider S, Muirhead G, Thway K, Newbold K, Coffin RS, Vile RG, Kim D, McLaughlin M, et al. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. Journal For Immunotherapy of Cancer. 8. PMID 32759235 DOI: 10.1136/Jitc-2020-000698 |
0.456 |
|
| 2020 |
Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Tonne J, Schuelke M, Ayasoufi K, Driscoll CB, Shim KG, Reynolds P, Monie DD, Johnson AJ, Coffey M, Young SL, ... ... Vile R, et al. Oncolytic virus-derived type I interferon restricts CAR T cell therapy. Nature Communications. 11: 3187. PMID 32581235 DOI: 10.1038/S41467-020-17011-Z |
0.848 |
|
| 2020 |
Wongthida P, Schuelke MR, Driscoll CB, Kottke T, Thompson JM, Tonne J, Stone C, Huff AL, Wetmore C, Davies JA, Parker AL, Evgin L, Vile RG. Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors. Neuro-Oncology. PMID 32459315 DOI: 10.1093/Neuonc/Noaa126 |
0.792 |
|
| 2020 |
McLaughlin M, Pedersen M, Roulstone V, Bergerhoff KF, Smith HG, Whittock H, Kyula JN, Dillon MT, Pandha HS, Vile R, Melcher AA, Harrington KJ. The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism. Molecular Therapy Oncolytics. 16: 238-249. PMID 32128359 DOI: 10.1016/J.Omto.2020.01.001 |
0.367 |
|
| 2020 |
Driscoll CB, Schuelke MR, Kottke T, Thompson JM, Wongthida P, Tonne JM, Huff AL, Miller A, Shim KG, Molan A, Wetmore C, Selby P, Samson A, Harrington K, Pandha H, ... ... Vile RG, et al. APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nature Communications. 11: 790. PMID 32034147 DOI: 10.1038/S41467-020-14568-7 |
0.807 |
|
| 2020 |
Eckert EC, Nace RA, Tonne JM, Evgin L, Vile RG, Russell SJ. Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9. Molecular Therapy Oncolytics. 16: 63-74. PMID 31930167 DOI: 10.1016/J.Omto.2019.12.003 |
0.631 |
|
| 2019 |
Schuelke MR, Wongthida P, Thompson J, Kottke T, Driscoll CB, Huff AL, Shim KG, Coffey M, Pulido J, Evgin L, Vile RG. Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity. Journal For Immunotherapy of Cancer. 7: 188. PMID 31315671 DOI: 10.1186/S40425-019-0673-2 |
0.775 |
|
| 2019 |
Jennings VA, Scott GB, Rose AMS, Scott KJ, Migneco G, Keller B, Reilly K, Donnelly O, Peach H, Dewar D, Harrington KJ, Pandha H, Samson A, Vile RG, Melcher AA, et al. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31053413 DOI: 10.1016/J.Ymthe.2019.04.008 |
0.568 |
|
| 2019 |
Evgin L, Huff AL, Kottke T, Thompson J, Molan AM, Driscoll CB, Schuelke M, Shim KG, Wongthida P, Ilett EJ, Kaluza Smith K, Harris RS, Coffey M, Pulido JS, Pandha H, ... ... Vile RG, et al. Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from Frontline Treatment. Cancer Immunology Research. PMID 30940643 DOI: 10.1158/2326-6066.Cir-18-0013 |
0.827 |
|
| 2019 |
Vile R, Evgin L, Kottke T, Schuelke M, Driscoll CB, Huff AL, Thompson J, Molan A, Harris RS, Pulido JS, Wongthida P. Abstract B138: Cancer immunotherapy with APOBEC3B-induced heteroclitic library tumor cell vaccines and immune checkpoint blockade Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-B138 |
0.785 |
|
| 2019 |
Huff AL, Wongthida P, Kottke T, Thompson J, Driscoll CB, Schuelke M, Shim KG, Harris RS, Molan A, Pulido JS, Selby PJ, Harrington KJ, Melcher A, Evgin L, Vile R. Abstract A133: APOBEC3 confers resistance to oncolytic VSV therapy Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A133 |
0.761 |
|
| 2019 |
Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Sampson J, Perez LS, Vile R. Abstract A029: Unexpected antagonism between oncolytic virus derived type I interferon and EGFRvIII CAR T-cells Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A029 |
0.797 |
|
| 2018 |
Huff AL, Wongthida P, Kottke T, Thompson JM, Driscoll CB, Schuelke M, Shim KG, Harris RS, Molan A, Pulido JS, Selby PJ, Harrington KJ, Melcher A, Evgin L, Vile RG. APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Molecular Therapy Oncolytics. 11: 1-13. PMID 30294666 DOI: 10.1016/J.Omto.2018.08.003 |
0.757 |
|
| 2018 |
Berkeley RA, Steele LP, Mulder AA, van den Wollenberg DJM, Kottke TJ, Thompson J, Coffey M, Hoeben RC, Vile RG, Melcher A, Ilett EJ. Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy. Cancer Immunology Research. PMID 30209061 DOI: 10.1158/2326-6066.Cir-18-0309 |
0.475 |
|
| 2018 |
Forbes NS, Coffin RS, Deng L, Evgin L, Fiering S, Giacalone M, Gravekamp C, Gulley JL, Gunn H, Hoffman RM, Kaur B, Liu K, Lyerly HK, Marciscano AE, Moradian E, ... ... Vile RG, et al. White paper on microbial anti-cancer therapy and prevention. Journal For Immunotherapy of Cancer. 6: 78. PMID 30081947 DOI: 10.1186/S40425-018-0381-3 |
0.377 |
|
| 2018 |
Annels NE, Arif M, Simpson GR, Denyer M, Moller-Levet C, Mansfield D, Butler R, Shafren D, Au G, Knowles M, Harrington K, Vile R, Melcher A, Pandha H. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus. Molecular Therapy Oncolytics. 9: 1-12. PMID 29989024 DOI: 10.1016/J.Omto.2018.02.001 |
0.484 |
|
| 2018 |
Uusi-Kerttula H, Davies JA, Thompson J, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile R, Chester JD, Parker AL. Ad5-A20 - a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29798908 DOI: 10.1158/1078-0432.Ccr-18-1089 |
0.704 |
|
| 2018 |
Vile RG. The Immune System in Oncolytic Immunovirotherapy: Gospel, Schism and Heresy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29573976 DOI: 10.1016/J.Ymthe.2018.03.007 |
0.329 |
|
| 2018 |
Khan AA, Paget JT, McLaughlin M, Kyula JN, Wilkinson MJ, Pencavel T, Mansfield D, Roulstone V, Seth R, Halle M, Somaiah N, Boult JKR, Robinson SP, Pandha HS, Vile RG, et al. Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues. Science Translational Medicine. 10. PMID 29367346 DOI: 10.1126/Scitranslmed.Aar2041 |
0.376 |
|
| 2018 |
Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, ... ... Vile RG, et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science Translational Medicine. 10. PMID 29298869 DOI: 10.1126/Scitranslmed.Aam7577 |
0.45 |
|
| 2018 |
Schuelke M, Evgin L, Wongthida P, Thompson J, Kottke T, Sanchez-Perez L, Sampson J, Vile R. IMMU-12. T-CELL THERAPIES DEMONSTRATE EFFICACY WITHOUT TOXICITY IN IMMUNOCOMPETENT MODELS OF BRAINSTEM TUMORS Neuro-Oncology. 20: i101-i101. DOI: 10.1093/Neuonc/Noy059.328 |
0.797 |
|
| 2017 |
Kottke T, Evgin L, Shim KG, Rommelfanger D, Boisgerault N, Zaidi S, Diaz RM, Thompson J, Ilett E, Coffey M, Selby P, Pandha H, Harrington K, Melcher A, Vile R. Subversion of NK Cell and TNF-alpha Immune Surveillance Drives Tumor Recurrence. Cancer Immunology Research. PMID 29038298 DOI: 10.1158/2326-6066.Cir-17-0175 |
0.55 |
|
| 2017 |
Cockle JV, Brüning-Richardson A, Scott KJ, Thompson J, Kottke T, Morrison E, Ismail A, Carcaboso AM, Rose A, Selby P, Conner J, Picton S, Short S, Vile R, Melcher A, et al. Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. Molecular Therapy Oncolytics. 5: 75-86. PMID 28547002 DOI: 10.1016/J.Omto.2017.04.002 |
0.492 |
|
| 2017 |
Shim KG, Zaidi S, Thompson J, Kottke T, Evgin L, Rajani KR, Schuelke M, Driscoll CB, Huff A, Pulido JS, Vile RG. Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28237836 DOI: 10.1016/J.Ymthe.2017.01.023 |
0.576 |
|
| 2017 |
Atherton MJ, Evgin L, Keller BA, Shenouda MM, Stephenson KB, Vile RG, Bell JC, Evans DH, Lichty BD. Infectious Optimism following the 10th International Oncolytic Virus Meeting Molecular Therapy - Oncolytics. 7: 12-16. DOI: 10.1016/J.Omto.2017.08.004 |
0.357 |
|
| 2016 |
Kottke T, Shim KG, Alonso-Camino V, Zaidi S, Maria Diaz R, Pulido J, Thompson J, Rajani KR, Evgin L, Ilett E, Pandha H, Harrington K, Selby P, Melcher A, Vile R. Immunogenicity of self tumor associated proteins is enhanced through protein truncation. Molecular Therapy Oncolytics. 3: 16030. PMID 27933315 DOI: 10.1038/Mto.2016.30 |
0.526 |
|
| 2016 |
Ilett E, Kottke T, Thompson J, Rajani K, Zaidi S, Evgin L, Coffey M, Ralph C, Diaz R, Pandha H, Harrington K, Selby P, Bram R, Melcher A, Vile R. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumor therapy. Gene Therapy. PMID 27779616 DOI: 10.1038/Gt.2016.70 |
0.556 |
|
| 2016 |
Vile RG. Socializing Individualized T-Cell Cancer Immunotherapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 24: 1170-3. PMID 27506377 DOI: 10.1038/Mt.2016.132 |
0.502 |
|
| 2016 |
Sun CW, Willmon C, Wu LC, Knopick P, Thoerner J, Vile R, Townes TM, Terman DS. Sickle Cells Abolish Melanoma Tumorigenesis in Hemoglobin SS Knockin Mice and Augment the Tumoricidal Effect of Oncolytic Virus In Vivo. Frontiers in Oncology. 6: 166. PMID 27458571 DOI: 10.3389/Fonc.2016.00166 |
0.498 |
|
| 2016 |
Mansfield DC, Kyula JN, Rosenfelder N, Chao-Chu J, Kramer-Marek G, Khan AA, Roulstone V, McLaughlin M, Melcher AA, Vile RG, Pandha HS, Khoo V, Harrington KJ. Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene Therapy. PMID 26814609 DOI: 10.1038/Gt.2016.5 |
0.473 |
|
| 2016 |
Cockle JV, Ilett E, Bruning-Richardson A, Thompson J, Kottke T, Scott K, Morrison EE, Ismail A, Rose A, Picton S, Vile R, Selby PJ, Short SC, Melcher A. Hg-08Oncolytic Herpes Simplex Virus: An Anti-Invasive Therapeutic Strategy For Paediatric High Grade Glioma And Diffuse Intrinsic Pontine Glioma Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now073.07 |
0.352 |
|
| 2016 |
Kottke T, Rommelfanger D, Shim KG, Pulido J, Thompson J, Rajani K, Bobr O, Selby P, Ilett E, Melcher A, Vile R. 749. Escape from Tumor Dormancy Following Gene- or Viro-Therapies Is Mediated by Acquisition of a Phenotype in Which Innate Immune Surveillance Actively Drives Tumor Cell Recurrence Molecular Therapy. 24: S296. DOI: 10.1016/S1525-0016(16)33557-2 |
0.584 |
|
| 2016 |
Schuelke M, Evgin L, Kottke T, Thompson J, Driscoll C, Ilett E, Cockle J, NageswaraRao A, Bram R, Melcher A, Vile R. 197. Balancing Anti-Tumor Efficacy with Local Inflammatory Toxicity for the Treatment of Diffuse Intrinsic Pontine Glioma and Other Brain Tumors Molecular Therapy. 24: S77. DOI: 10.1016/S1525-0016(16)33006-4 |
0.513 |
|
| 2016 |
Rajani K, Shim KG, Kazemi NY, Gendron W, Kottke T, Molan A, Driscoll C, Harris R, Vile R. 64. Generation of Tumor Cells Resistant to Oncolysis Is Mediated Through Virus Induced APOBEC Expression Molecular Therapy. 24: S28. DOI: 10.1016/S1525-0016(16)32873-8 |
0.574 |
|
| 2016 |
Kottke T, Shim KG, Evgin L, Alonso-Camino V, Zaidi S, Diaz R, Pulido J, Thompson J, Rajani K, Huff A, Ilett E, Pandha H, Harrington K, Selby P, Melcher A, ... Vile R, et al. 63. Immunogenicity of Self Tumor Associated Antigens Is Enhanced Through Protein Truncation Molecular Therapy. 24: S28. DOI: 10.1016/S1525-0016(16)32872-6 |
0.476 |
|
| 2015 |
Rajani KR, Vile RG. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses. 7: 5889-901. PMID 26580645 DOI: 10.3390/V7112914 |
0.598 |
|
| 2015 |
Blanchard M, Shim KG, Grams MP, Rajani K, Diaz RM, Furutani KM, Thompson J, Olivier KR, Park SS, Markovic SN, Pandha H, Melcher A, Harrington K, Zaidi S, Vile R. Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy. International Journal of Radiation Oncology, Biology, Physics. 93: 577-87. PMID 26461000 DOI: 10.1016/J.Ijrobp.2015.07.2274 |
0.507 |
|
| 2015 |
Cockle JV, Rajani K, Zaidi S, Kottke T, Thompson J, Diaz RM, Shim K, Peterson T, Parney IF, Short S, Selby P, Ilett E, Melcher A, Vile R. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro-Oncology. PMID 26409567 DOI: 10.1093/Neuonc/Nov173 |
0.535 |
|
| 2015 |
Rajani K, Parrish C, Kottke T, Thompson J, Zaidi S, Ilett L, Shim KG, Diaz RM, Pandha H, Harrington K, Coffey M, Melcher A, Vile R. Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26310630 DOI: 10.1038/Mt.2015.156 |
0.569 |
|
| 2015 |
Felts SJ, Van Keulen VP, Hansen MJ, Bell MP, Allen K, Belachew AA, Vile RG, Cunningham JM, Hoskin TL, Pankratz VS, Pease LR. Widespread Non-Canonical Epigenetic Modifications in MMTV-NeuT Breast Cancer. Neoplasia (New York, N.Y.). 17: 348-57. PMID 25925377 DOI: 10.1016/J.Neo.2015.02.006 |
0.34 |
|
| 2015 |
Seth R, Khan AA, Pencavel TD, Wilkinson MJ, Kyula JN, Simpson G, Pandha H, Melcher A, Vile R, Harris PA, Harrington KJ. Adenovirally delivered enzyme prodrug therapy with herpes simplex virus-thymidine kinase in composite tissue free flaps shows therapeutic efficacy in rat models of glioma. Plastic and Reconstructive Surgery. 135: 475-87. PMID 25626794 DOI: 10.1097/Prs.0000000000000878 |
0.368 |
|
| 2015 |
Zaidi S, Blanchard M, Shim K, Ilett E, Rajani K, Parrish C, Boisgerault N, Kottke T, Thompson J, Celis E, Pulido J, Selby P, Pandha H, Melcher A, Harrington K, ... Vile R, et al. Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 845-56. PMID 25544599 DOI: 10.1038/Mt.2014.253 |
0.539 |
|
| 2015 |
Roulstone V, Khan K, Pandha HS, Rudman S, Coffey M, Gill GM, Melcher AA, Vile R, Harrington KJ, de Bono J, Spicer J. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1305-12. PMID 25424857 DOI: 10.1158/1078-0432.Ccr-14-1770 |
0.466 |
|
| 2015 |
Zaidi S, Shim K, Rajani K, Diaz R, Ilett E, Kottke T, Thompson J, Selby P, Harrington K, Pandha H, Melcher A, Coffey M, Vile R. Abstract B88: Combination therapy of reovirus and checkpoint inhibition Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-B88 |
0.614 |
|
| 2015 |
Jebar A, Ilett L, Kottke T, West E, Scott K, Thomson S, Coffey M, Nuovo G, Short S, Vile R, Melcher A. Abstract A49: Systemic oncolytic reovirus for the treatment of primary and secondary brain tumors Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A49 |
0.514 |
|
| 2015 |
Rajani K, Parrish C, Shim K, Ilett L, Errington-Mais F, Thompson J, Kottke T, Maria-Diaz R, Selby P, Pandha H, Harrington K, Melcher A, Coffey M, Zaidi S, Vile R. Abstract 1360: Combination therapy of reovirus and PD-1 blockade effectively establishes tumor control via innate and adaptive immune responses Cancer Research. 75: 1360-1360. DOI: 10.1158/1538-7445.Am2015-1360 |
0.581 |
|
| 2015 |
Rao G, Ling X, Doucette T, Yang Y, Kong L, Wei J, Fuller G, Nwajei F, Zhou S, Caruso H, Vile R, Heimberger A. IMPS-34INNATE IMMUNOLOGICAL COMPENSATORY CONTROL OF GLIOMAGENESIS AND MALIGNANT TRANSFORMATION IN MURINE CD8α KNOCKOUT MODELS Neuro-Oncology. 17: v120.3-v120. DOI: 10.1093/Neuonc/Nov217.33 |
0.461 |
|
| 2015 |
Shim KG, Diaz R, Zaidi S, Blanchard M, Grams M, Kottke T, Thompson J, Markovic SN, Vile RG. 418. Effective Treatment of Oligometastatic Melanoma Using Combination VSV Viroimmunotherapy and Stereotactic Radiotherapy Molecular Therapy. 23: S165-S166. DOI: 10.1016/S1525-0016(16)34027-8 |
0.535 |
|
| 2015 |
Rajani K, Shim K, Parrish C, Ilett L, Kottke T, Pulido J, Thompson J, Pandha H, Harrington K, Melcher A, Errington F, Diaz R, Coffey M, Zaidi S, Vile R. 69. Combination Therapy of Reovirus and PD-1 Blockade Effectively Establishes Tumor Control Via Innate and Adaptive Immune Responses Molecular Therapy. 23: S30. DOI: 10.1016/S1525-0016(16)33674-7 |
0.568 |
|
| 2014 |
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, ... ... Vile R, et al. Classification of current anticancer immunotherapies. Oncotarget. 5: 12472-508. PMID 25537519 DOI: 10.18632/Oncotarget.2998 |
0.483 |
|
| 2014 |
Vile RG. How to train your oncolytic virus: the immunological sequel. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1881-4. PMID 25365984 DOI: 10.1038/Mt.2014.188 |
0.549 |
|
| 2014 |
Boisgerault N, Vile RG. Trick and treat: Ambushing recurrent tumors before they get out of the door. Oncoimmunology. 3: e27811. PMID 25339997 DOI: 10.4161/onci.27811 |
0.43 |
|
| 2014 |
Alonso-Camino V, Rajani K, Kottke T, Rommelfanger-Konkol D, Zaidi S, Thompson J, Pulido J, Ilett E, Donnelly O, Selby P, Pandha H, Melcher A, Harrington K, Diaz RM, Vile R. The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1936-48. PMID 25059678 DOI: 10.1038/Mt.2014.134 |
0.816 |
|
| 2014 |
Ilett E, Kottke T, Donnelly O, Thompson J, Willmon C, Diaz R, Zaidi S, Coffey M, Selby P, Harrington K, Pandha H, Melcher A, Vile R. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1851-63. PMID 24957982 DOI: 10.1038/Mt.2014.118 |
0.576 |
|
| 2014 |
Boisgerault N, Vile RG. [Tumor relapse: what makes you stronger can kill you]. MéDecine Sciences : M/S. 30: 355-7. PMID 24801027 DOI: 10.1051/Medsci/20143004006 |
0.48 |
|
| 2014 |
Jennings VA, Ilett EJ, Scott KJ, West EJ, Vile R, Pandha H, Harrington K, Young A, Hall GD, Coffey M, Selby P, Errington-Mais F, Melcher AA. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. International Journal of Cancer. Journal International Du Cancer. 134: 1091-101. PMID 23982804 DOI: 10.1002/Ijc.28450 |
0.549 |
|
| 2014 |
Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, Mclaughlin M, Roulstone V, Zaidi S, Pencavel T, Touchefeu Y, Seth R, Chen NG, Yu YA, Zhang Q, Melcher AA, Vile RG, et al. Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/EBRAF mutant melanoma depends on JNK and TNF-α signaling Oncogene. 33: 1700-1712. PMID 23624923 DOI: 10.1038/Onc.2013.112 |
0.397 |
|
| 2014 |
Jebar A, West E, Scott K, Thomson S, Corns R, Coffey MC, Rose A, Nuovo G, Ryan M, Errington-Mais F, Ralph C, Twelves C, Griffin S, Harrington KJ, Pandha HS, ... ... Vile R, et al. Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients. Journal of Clinical Oncology. 32: 3104-3104. DOI: 10.1200/Jco.2014.32.15_Suppl.3104 |
0.327 |
|
| 2014 |
Donnelly O, Ilett E, Kottke T, Thompson J, Vile R, Melcher A. Cytokine-enhanced intravenous oncolytic virotherapy The Lancet. 383. DOI: 10.1016/S0140-6736(14)60305-6 |
0.402 |
|
| 2013 |
Rommelfanger DM, Grau MC, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG. The Efficacy Versus Toxicity Profile of Combination Virotherapy and TLR Immunotherapy Highlights the Danger of Administering TLR Agonists to Oncolytic Virus-treated Mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 348-357. PMID 28160842 DOI: 10.1038/mt.2012.204 |
0.403 |
|
| 2013 |
Rommelfanger DM, Grau MC, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG. Erratum: The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice (Molecular Therapy (2013) 21 (348-357) DOI: 10.1038/mt.2012.204) Molecular Therapy. 21. PMID 28153327 DOI: 10.1038/Mt.2013.48 |
0.382 |
|
| 2013 |
Kottke T, Boisgerault N, Diaz RM, Donnelly O, Rommelfanger-Konkol D, Pulido J, Thompson J, Mukhopadhyay D, Kaspar R, Coffey M, Pandha H, Melcher A, Harrington K, Selby P, Vile R. Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nature Medicine. 19: 1625-31. PMID 24240185 DOI: 10.1038/Nm.3397 |
0.819 |
|
| 2013 |
Boisgerault N, Kottke T, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol D, Embry A, Saenz D, Poeschla E, Pandha H, Harrington K, Melcher A, Selby P, Vile R. Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1507-16. PMID 23752316 DOI: 10.1038/Mt.2013.116 |
0.828 |
|
| 2013 |
Alonso-Camino V, Sánchez-Martín D, Compte M, Nuñez-Prado N, Diaz RM, Vile R, Alvarez-Vallina L. CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors. Molecular Therapy. Nucleic Acids. 2: e93. PMID 23695536 DOI: 10.1038/Mtna.2013.19 |
0.501 |
|
| 2013 |
Kaluza KM, Vile R. Improving the outcome of adoptive cell transfer by targeting tumor escape. Oncoimmunology. 2: e22059. PMID 23483796 DOI: 10.4161/Onci.22059 |
0.842 |
|
| 2013 |
Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, Coffey M, Selby P, Cook GP, Vile R, Harrington KJ, Toogood G, Melcher AA. Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. International Journal of Cancer. Journal International Du Cancer. 132: 2327-38. PMID 23114986 DOI: 10.1002/Ijc.27918 |
0.44 |
|
| 2013 |
Rommelfanger DM, Compte M, Grau MC, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 348-57. PMID 23011032 DOI: 10.1038/Mt.2012.204 |
0.504 |
|
| 2013 |
Mansfield D, Pencavel T, Kyula JN, Zaidi S, Roulstone V, Thway K, Karapanagiotou L, Khan AA, McLaughlin M, Touchefeu Y, Seth R, Melcher AA, Vile RG, Pandha HS, Harrington KJ. Oncolytic Vaccinia virus and radiotherapy in head and neck cancer Oral Oncology. 49: 108-118. PMID 22925693 DOI: 10.1016/J.Oraloncology.2012.07.019 |
0.424 |
|
| 2013 |
Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, Harrington K, Vile R, Russell S, Selby P, Melcher AA. Measles virus causes immunogenic cell death in human melanoma. Gene Therapy. 20: 7-15. PMID 22170342 DOI: 10.1038/Gt.2011.205 |
0.43 |
|
| 2013 |
Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R, Melcher AA. Recent clinical experience with oncolytic viruses. Current Pharmaceutical Biotechnology. 13: 1834-41. PMID 21740364 DOI: 10.2174/138920112800958904 |
0.341 |
|
| 2012 |
Hall K, Scott KJ, Rose A, Desborough M, Harrington K, Pandha H, Parrish C, Vile R, Coffey M, Bowen D, Errington-Mais F, Melcher AA. Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia. Bioresearch Open Access. 1: 3-15. PMID 23515241 DOI: 10.1089/Biores.2012.0205 |
0.507 |
|
| 2012 |
Donnelly OG, Melcher AA, Vile RG, Pulido J. What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma? Immunotherapy. 4: 749-51. PMID 22947000 DOI: 10.2217/Imt.12.65 |
0.323 |
|
| 2012 |
Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, White C, Bhide S, Nuovo G, Coffey M, Thompson B, Jebar A, Errington F, Melcher AA, Vile RG, et al. Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. Bmc Cancer. 12: 368. PMID 22920673 DOI: 10.1186/1471-2407-12-368 |
0.369 |
|
| 2012 |
Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, et al. Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1998-2003. PMID 22871663 DOI: 10.1038/Mt.2012.146 |
0.365 |
|
| 2012 |
Rommelfanger DM, Wongthida P, Diaz RM, Kaluza KM, Thompson JM, Kottke TJ, Vile RG. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Research. 72: 4753-64. PMID 22836753 DOI: 10.1158/0008-5472.Can-12-0600 |
0.854 |
|
| 2012 |
Kaluza KM, Kottke T, Diaz RM, Rommelfanger D, Thompson J, Vile R. Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape. Human Gene Therapy. 23: 1054-64. PMID 22734672 DOI: 10.1089/Hum.2012.030 |
0.855 |
|
| 2012 |
Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, Beirne D, West EJ, Jennings VA, Rose A, Kyula J, Fraser S, Dave R, Anthoney DA, Merrick A, ... ... Vile R, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Science Translational Medicine. 4: 138ra77. PMID 22700953 DOI: 10.1126/Scitranslmed.3003578 |
0.565 |
|
| 2012 |
Nuovo GJ, Garofalo M, Valeri N, Roulstone V, Volinia S, Cohn DE, Phelps M, Harrington KJ, Vile R, Melcher A, Galanis E, Sehl S, Adair R, Scott K, Rose A, et al. Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 25: 1333-44. PMID 22699519 DOI: 10.1038/Modpathol.2012.95 |
0.338 |
|
| 2012 |
Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, Rommelfanger D, Ilett E, Pease L, Pandha H, Harrington K, Selby P, Melcher A, Vile R. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nature Biotechnology. 30: 337-43. PMID 22426030 DOI: 10.1038/Nbt.2157 |
0.807 |
|
| 2012 |
Guedan S, Grases D, Rojas JJ, Gros A, Vilardell F, Vile R, Mercade E, Cascallo M, Alemany R. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution Gene Therapy. 19: 1048-1057. PMID 22113313 DOI: 10.1038/Gt.2011.184 |
0.589 |
|
| 2012 |
Vile R, Melcher A. An intravenous stimulus package for oncolytic virotherapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1930-2. PMID 22051602 DOI: 10.1038/Mt.2011.217 |
0.507 |
|
| 2012 |
Kaluza KM, Thompson JM, Kottke TJ, Flynn Gilmer HC, Knutson DL, Vile RG. Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants. International Journal of Cancer. Journal International Du Cancer. 131: 844-54. PMID 21935923 DOI: 10.1002/Ijc.26447 |
0.857 |
|
| 2012 |
Rommelfanger DM, Offord CP, Dev J, Bajzer Z, Vile RG, Dingli D. Dynamics of melanoma tumor therapy with vesicular stomatitis virus: Explaining the variability in outcomes using mathematical modeling Gene Therapy. 19: 543-549. PMID 21918546 DOI: 10.1038/Gt.2011.132 |
0.573 |
|
| 2012 |
Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM, Chong H, Ilett E, Chester J, Pandha H, Harrington K, Selby P, Melcher A, Vile R. Erratum: Corrigendum: Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors Nature Medicine. 18: 1445-1445. DOI: 10.1038/Nm0912-1445D |
0.719 |
|
| 2011 |
Kottke T, Chester J, Ilett E, Thompson J, Diaz R, Coffey M, Selby P, Nuovo G, Pulido J, Mukhopadhyay D, Pandha H, Harrington K, Melcher A, Vile R. Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1802-12. PMID 21792179 DOI: 10.1038/Mt.2011.147 |
0.472 |
|
| 2011 |
Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM, Chong H, Ilett E, Chester J, Pandha H, Harrington K, Selby P, Melcher A, Vile R. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature Medicine. 17: 854-9. PMID 21685898 DOI: 10.1038/Nm.2390 |
0.808 |
|
| 2011 |
Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R, Pandha HS. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. Bmc Cancer. 11: 221. PMID 21645351 DOI: 10.1186/1471-2407-11-221 |
0.374 |
|
| 2011 |
Naik JD, Twelves CJ, Selby PJ, Vile RG, Chester JD. Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4214-24. PMID 21576084 DOI: 10.1158/1078-0432.Ccr-10-2848 |
0.523 |
|
| 2011 |
Ilett EJ, Bárcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Limpens RW, Mommaas M, Hoeben RC, Vile RG, Melcher AA. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2767-76. PMID 21389099 DOI: 10.1158/1078-0432.Ccr-10-3266 |
0.426 |
|
| 2011 |
Wongthida P, Diaz RM, Pulido C, Rommelfanger D, Galivo F, Kaluza K, Kottke T, Thompson J, Melcher A, Vile R. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Human Gene Therapy. 22: 1343-53. PMID 21366404 DOI: 10.1089/Hum.2010.216 |
0.853 |
|
| 2011 |
Steele L, Errington F, Prestwich R, Ilett E, Harrington K, Pandha H, Coffey M, Selby P, Vile R, Melcher A. Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming. Molecular Cancer. 10: 20. PMID 21338484 DOI: 10.1186/1476-4598-10-20 |
0.339 |
|
| 2011 |
Willmon C, Diaz RM, Wongthida P, Galivo F, Kottke T, Thompson J, Albelda S, Harrington K, Melcher A, Vile R. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 140-9. PMID 20978474 DOI: 10.1038/Mt.2010.224 |
0.809 |
|
| 2011 |
Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Melcher A, Vile R. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 150-8. PMID 20959810 DOI: 10.1038/Mt.2010.225 |
0.791 |
|
| 2010 |
Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5564-72. PMID 20926400 DOI: 10.1158/1078-0432.Ccr-10-1233 |
0.383 |
|
| 2010 |
Heinemann L, Simpson GR, Annels NE, Vile R, Melcher A, Prestwich R, Harrington KJ, Pandha HS. The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 2085-93. PMID 20842107 DOI: 10.1038/Mt.2010.189 |
0.516 |
|
| 2010 |
Hingorani M, White CL, Zaidi S, Pandha HS, Melcher AA, Bhide SA, Nutting CM, Syrigos KN, Vile RG, Vassaux G, Harrington KJ. Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1599-605. PMID 20588260 DOI: 10.1038/Mt.2010.120 |
0.369 |
|
| 2010 |
Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Pulido J, Pavelko K, Pease L, Melcher A, Vile R. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Research. 70: 4539-49. PMID 20484025 DOI: 10.1158/0008-5472.Can-09-4658 |
0.79 |
|
| 2010 |
Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3067-77. PMID 20484020 DOI: 10.1158/1078-0432.Ccr-10-0054 |
0.421 |
|
| 2010 |
Pencavel T, Seth R, Hayes A, Melcher A, Pandha H, Vile R, Harrington KJ. Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow? Gene Therapy. 17: 949-60. PMID 20445580 DOI: 10.1038/Gt.2010.48 |
0.446 |
|
| 2010 |
Harvey TJ, Burdon D, Steele L, Ingram N, Hall GD, Selby PJ, Vile RG, Cooper PA, Shnyder SD, Chester JD. Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor Gene Therapy. 17: 1000-1010. PMID 20410926 DOI: 10.1038/Gt.2010.45 |
0.358 |
|
| 2010 |
Kottke T, Hall G, Pulido J, Diaz RM, Thompson J, Chong H, Selby P, Coffey M, Pandha H, Chester J, Melcher A, Harrington K, Vile R. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. The Journal of Clinical Investigation. 120: 1551-60. PMID 20364090 DOI: 10.1172/Jci41431 |
0.556 |
|
| 2010 |
Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics Cytokine and Growth Factor Reviews. 21: 91-98. PMID 20223697 DOI: 10.1016/J.Cytogfr.2010.02.006 |
0.339 |
|
| 2010 |
Hingorani M, Spitzweg C, Vassaux G, Newbold K, Melcher A, Pandha H, Vile R, Harrington K. The biology of the sodium iodide symporter and its potential for targeted gene delivery. Current Cancer Drug Targets. 10: 242-67. PMID 20201784 DOI: 10.2174/156800910791054194 |
0.309 |
|
| 2010 |
Smerdou C, Ochoa C, Quetglas JI, Fontanellas A, Gonzalez-Aseguinolaza G, Vile RG, Melero I. Immunology and gene therapy: shoulder to shoulder into the fray. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 456-9. PMID 20195262 DOI: 10.1038/Mt.2010.7 |
0.387 |
|
| 2010 |
Lagouros E, Salomao D, Thorland E, Hodge DO, Vile R, Pulido JS. Infiltrative T regulatory cells in enucleated uveal melanomas. Transactions of the American Ophthalmological Society. 107: 223-8. PMID 20126498 |
0.418 |
|
| 2010 |
Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, Melcher A, Vile R. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Therapy. 17: 158-70. PMID 20016540 DOI: 10.1038/Gt.2009.161 |
0.806 |
|
| 2010 |
Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, Kottke T, Barber GN, Melcher A, Vile RG. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Human Gene Therapy. 21: 439-50. PMID 19922169 DOI: 10.1089/Hum.2009.143 |
0.823 |
|
| 2010 |
Jenks N, Myers R, Greiner SM, Thompson J, Mader EK, Greenslade A, Griesmann GE, Federspiel MJ, Rakela J, Borad MJ, Vile RG, Barber GN, Meier TR, Blanco MC, Carlson SK, et al. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Human Gene Therapy. 21: 451-62. PMID 19911974 DOI: 10.1089/Hum.2009.111 |
0.327 |
|
| 2010 |
Saloura V, Wang LC, Fridlender ZG, Sun J, Cheng G, Kapoor V, Sterman DH, Harty RN, Okumura A, Barber GN, Vile RG, Federspiel MJ, Russell SJ, Litzky L, Albelda SM. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Human Gene Therapy. 21: 51-64. PMID 19715403 DOI: 10.1089/Hum.2009.088 |
0.367 |
|
| 2010 |
Wang LS, Saloura V, Alexander E, Cheng G, Kapoor V, Vile R, Thorne SH, Isaacs SN, Albelda SM. Abstract 1513: Pre-clinical evaluation of two oncolytic viral vectors expressing IFNβ in treatment of thoracic cancer: Vaccinia virus versus vesicular stomatitis virus Cancer Research. 70: 1513-1513. DOI: 10.1158/1538-7445.Am10-1513 |
0.533 |
|
| 2009 |
Pandha H, Melcher A, Harrington K, Vile R. Oncolytic Viruses: Time to Compare, Contrast, and Combine? Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 934-935. PMID 28182912 DOI: 10.1038/Mt.2009.86 |
0.565 |
|
| 2009 |
Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Research. 69: 7713-20. PMID 19773437 DOI: 10.1158/0008-5472.Can-09-1013 |
0.763 |
|
| 2009 |
Kottke T, Pulido J, Thompson J, Sanchez-Perez L, Chong H, Calderwood SK, Selby P, Harrington K, Strome SE, Melcher A, Vile RG. Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Research. 69: 7767-74. PMID 19738045 DOI: 10.1158/0008-5472.Can-09-1597 |
0.503 |
|
| 2009 |
Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. Journal of Immunology (Baltimore, Md. : 1950). 183: 4312-21. PMID 19734207 DOI: 10.4049/Jimmunol.0901074 |
0.508 |
|
| 2009 |
Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1667-76. PMID 19690519 DOI: 10.1038/Mt.2009.194 |
0.582 |
|
| 2009 |
Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Human Gene Therapy. 20: 1119-32. PMID 19630549 DOI: 10.1089/Hum.2009.135 |
0.506 |
|
| 2009 |
Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4374-81. PMID 19509134 DOI: 10.1158/1078-0432.Ccr-09-0334 |
0.556 |
|
| 2009 |
Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Vile RG, Melcher AA. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity Gene Therapy. 16: 689-699. PMID 19282847 DOI: 10.1038/Gt.2009.29 |
0.494 |
|
| 2009 |
Kottke T, Thompson J, Diaz RM, Pulido J, Willmon C, Coffey M, Selby P, Melcher A, Harrington K, Vile RG. Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 561-9. PMID 19147761 DOI: 10.1158/1078-0432.Ccr-08-1688 |
0.449 |
|
| 2008 |
Kottke T, Galivo F, Wongthida P, Maria Diaz R, Thompson J, Jevremovic D, Barber GN, Hall G, Chester J, Selby P, Harrington K, Melcher A, Vile RG. Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1217-1226. PMID 28178481 DOI: 10.1038/Mt.2008.83 |
0.801 |
|
| 2008 |
Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7358-66. PMID 19010851 DOI: 10.1158/1078-0432.Ccr-08-0831 |
0.467 |
|
| 2008 |
Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7127-37. PMID 18981012 DOI: 10.1158/1078-0432.Ccr-08-0524 |
0.41 |
|
| 2008 |
Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Review of Anticancer Therapy. 8: 1581-8. PMID 18925850 DOI: 10.1586/14737140.8.10.1581 |
0.451 |
|
| 2008 |
Kottke T, Diaz RM, Kaluza K, Pulido J, Galivo F, Wongthida P, Thompson J, Willmon C, Barber GN, Chester J, Selby P, Strome S, Harrington K, Melcher A, Vile RG. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1910-8. PMID 18827807 DOI: 10.1038/Mt.2008.212 |
0.846 |
|
| 2008 |
Kaluza K, Vile RG. Magnetic cells for cancer therapy: Adopting magnets for cell-based cancer therapies Gene Therapy. 15: 1511-1512. PMID 18719530 DOI: 10.1038/Gt.2008.139 |
0.781 |
|
| 2008 |
Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. Exploiting synergies between radiation and oncolytic viruses. Current Opinion in Molecular Therapeutics. 10: 362-70. PMID 18683101 |
0.31 |
|
| 2008 |
Hingorani M, White CL, Zaidi S, Merron A, Peerlinck I, Gore ME, Nutting CM, Pandha HS, Melcher AA, Vile RG, Vassaux G, Harrington KJ. Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4915-24. PMID 18676766 DOI: 10.1158/1078-0432.Ccr-07-4049 |
0.351 |
|
| 2008 |
Sekulic A, Haluska P, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, Swanson DL, Pockaj BA, Laman SD, Pittelkow MR, Markovic SN. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clinic Proceedings. 83: 825-46. PMID 18613999 DOI: 10.4065/83.7.825 |
0.372 |
|
| 2008 |
Hatfield P, Merrick AE, West E, O’Donnell D, Selby P, Vile R, Melcher AA. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. Journal of Immunotherapy. 31: 620-632. PMID 18600182 DOI: 10.1097/Cji.0B013E31818213Df |
0.514 |
|
| 2008 |
Guedan S, Gros A, Cascallo M, Vile R, Mercade E, Alemany R. Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication Gene Therapy. 15: 1240-1245. PMID 18509378 DOI: 10.1038/Gt.2008.94 |
0.366 |
|
| 2008 |
Kottke T, Galivo F, Wongthida P, Diaz RM, Thompson J, Jevremovic D, Barber GN, Hall G, Chester J, Selby P, Harrington K, Melcher A, Vile RG. Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1217-26. PMID 18431359 DOI: 10.1038/mt.2008.83 |
0.788 |
|
| 2008 |
Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, de Bono J, Selby P, Coffey M, Vile R, Melcher A. Reovirus activates human dendritic cells to promote innate antitumor immunity. Journal of Immunology (Baltimore, Md. : 1950). 180: 6018-26. PMID 18424722 DOI: 10.4049/Jimmunol.180.9.6018 |
0.474 |
|
| 2008 |
Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, Ilett LJ, Prestwich R, Pandha HS, Coffey M, Selby P, Vile R, Harrington KJ, Melcher AA. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Therapy. 15: 1257-70. PMID 18401435 DOI: 10.1038/Gt.2008.58 |
0.408 |
|
| 2008 |
White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, Melcher AA, Pandha HS, Harrington KJ. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial Gene Therapy. 15: 911-920. PMID 18323793 DOI: 10.1038/Gt.2008.21 |
0.414 |
|
| 2008 |
Qiao J, Wang H, Kottke T, Diaz RM, Willmon C, Hudacek A, Thompson J, Parato K, Bell J, Naik J, Chester J, Selby P, Harrington K, Melcher A, Vile RG. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Therapy. 15: 604-16. PMID 18305577 DOI: 10.1038/Sj.Gt.3303098 |
0.601 |
|
| 2008 |
Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, Thompson B, Vile RG, Heinemann L, Pandha HS, Errington F, Melcher AA, Harrington KJ. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 912-23. PMID 18245555 DOI: 10.1158/1078-0432.Ccr-07-1400 |
0.466 |
|
| 2008 |
Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, Thompson J, Selby P, de Bono J, Melcher A, Pandha H, Coffey M, Vile R, Harrington K. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 259-69. PMID 18172278 DOI: 10.1158/1078-0432.Ccr-07-1510 |
0.448 |
|
| 2008 |
White CL, Menghistu T, Twigger KR, Searle PF, Bhide SA, Vile RG, Melcher AA, Pandha HS, Harrington KJ. Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo. Gene Therapy. 15: 424-33. PMID 18079753 DOI: 10.1038/Sj.Gt.3303081 |
0.366 |
|
| 2008 |
Qiao J, Kottke T, Willmon C, Galivo F, Wongthida P, Diaz RM, Thompson J, Ryno P, Barber GN, Chester J, Selby P, Harrington K, Melcher A, Vile RG. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nature Medicine. 14: 37-44. PMID 18066076 DOI: 10.1038/Nm1681 |
0.779 |
|
| 2008 |
Merrick A, Diaz RM, O'Donnell D, Selby P, Vile R, Melcher A. Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy. Cancer Immunology, Immunotherapy : Cii. 57: 897-906. PMID 18057935 DOI: 10.1007/S00262-007-0426-9 |
0.398 |
|
| 2007 |
Kottke T, Sanchez-Perez L, Diaz RM, Thompson J, Chong H, Harrington K, Calderwood SK, Pulido J, Georgopoulos N, Selby P, Melcher A, Vile R. Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Research. 67: 11970-9. PMID 18089828 DOI: 10.1158/0008-5472.Can-07-2259 |
0.466 |
|
| 2007 |
Lang SI, Kottke T, Thompson J, Vile RG. Unbiased selection of bone marrow derived cells as carriers for cancer gene therapy. The Journal of Gene Medicine. 9: 927-37. PMID 17721895 DOI: 10.1002/Jgm.1089 |
0.509 |
|
| 2007 |
Larmonier N, Cathelin D, Larmonier C, Nicolas A, Merino D, Janikashvili N, Audia S, Bateman A, Thompson J, Kottke T, Hartung T, Katsanis E, Vile R, Bonnotte B. The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. Experimental Cell Research. 313: 2345-55. PMID 17466973 DOI: 10.1016/J.Yexcr.2007.03.027 |
0.47 |
|
| 2007 |
Sanchez-Perez L, Gough M, Qiao J, Thanarajasingam U, Kottke T, Ahmed A, Thompson JM, Maria Diaz R, Vile RG. Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells Gene Therapy. 14: 998-1009. PMID 17443216 DOI: 10.1038/Sj.Gt.3302935 |
0.605 |
|
| 2007 |
Smits PA, Kleppe LS, Witt TA, Mueske CS, Vile RG, Simari RD. Distribution of circulation-derived endothelial progenitors following systemic delivery. Endothelium : Journal of Endothelial Cell Research. 14: 1-5. PMID 17364891 DOI: 10.1080/10623320601177254 |
0.361 |
|
| 2007 |
Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, Valdes M, Barber G, Vile RG. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Research. 67: 2840-8. PMID 17363607 DOI: 10.1158/0008-5472.Can-06-3974 |
0.824 |
|
| 2007 |
Thanarajasingam U, Sanz L, Diaz R, Qiao J, Sanchez-Perez L, Kottke T, Thompson J, Chester J, Vile RG. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Research. 67: 300-8. PMID 17210711 DOI: 10.1158/0008-5472.Can-06-1017 |
0.561 |
|
| 2006 |
Vile RG. Viral mediated cell fusion: Viral fusion - The making, or breaking, of a tumour? Gene Therapy. 13: 1127-1130. PMID 17243200 DOI: 10.1038/Sj.Gt.3302762 |
0.359 |
|
| 2006 |
Zhang X, Dong H, Lin W, Voss S, Hinkley L, Westergren M, Tian G, Berry D, Lewellen D, Vile RG, Chen L, Farber DL, Strome SE. Human bone marrow: a reservoir for "enhanced effector memory" CD8+ T cells with potent recall function. Journal of Immunology (Baltimore, Md. : 1950). 177: 6730-7. PMID 17082586 DOI: 10.4049/Jimmunol.177.10.6730 |
0.345 |
|
| 2006 |
Sanchez-Perez L, Kottke T, Daniels GA, Diaz RM, Thompson J, Pulido J, Melcher A, Vile RG. Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. Journal of Immunology (Baltimore, Md. : 1950). 177: 4168-77. PMID 16951382 DOI: 10.4049/Jimmunol.177.6.4168 |
0.504 |
|
| 2006 |
Qiao J, Moreno J, Sanchez-Perez L, Kottke T, Thompson J, Caruso M, Diaz RM, Vile R. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Gene Therapy. 13: 1457-70. PMID 16724095 DOI: 10.1038/Sj.Gt.3302782 |
0.53 |
|
| 2006 |
Harrington K, Vile R. Virus smuggling, tax evasion and tumor assassination. Nature Medicine. 12: 507-509. PMID 16675994 DOI: 10.1038/Nm0506-507 |
0.559 |
|
| 2006 |
Kottke T, Qiao J, Diaz RM, Ahmed A, Vroman B, Thompson J, Sanchez-Perez L, Vile R. The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles. Gene Therapy. 13: 1166-77. PMID 16625245 DOI: 10.1038/Sj.Gt.3302722 |
0.515 |
|
| 2006 |
Cheong SC, Blangenois I, Franssen JD, Servais C, Phan V, Trakatelli M, Bruyns C, Vile R, Velu T, Brandenburger A. Generation of cell hybrids via a fusogenic cell line Journal of Gene Medicine. 8: 919-928. PMID 16602137 DOI: 10.1002/Jgm.906 |
0.367 |
|
| 2006 |
Errington F, Bateman A, Kottke T, Thompson J, Harrington K, Merrick A, Hatfield P, Selby P, Vile RG, Melcher A. Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy Clinical Cancer Research. 12: 1333-1341. PMID 16489091 DOI: 10.1158/1078-0432.Ccr-05-1113 |
0.489 |
|
| 2006 |
Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough M, O'Donnell D, Selby P, Vile R, Melcher A. Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Therapy. 13: 138-149. PMID 16136162 DOI: 10.1038/Sj.Gt.3302609 |
0.453 |
|
| 2006 |
Chester J, Ruchatz A, Gough M, Crittenden M, Chong H, Loïc-Cosset F, Diaz RM, Harrington K, Alvarez-Vallina L, Vile R. Erratum: Corrigendum: Tumor antigen—specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor—modified T cells Nature Biotechnology. 24: 1293-1293. DOI: 10.1038/Nbt1006-1293B |
0.44 |
|
| 2006 |
Qiao J, Wang H, Diaz RM, Ahmed A, Thompson J, Vile R. 812. Cellular Delivery of Gene Therapy Vectors Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.897 |
0.541 |
|
| 2006 |
Sanchez-Perez L, Daniels G, Kottke T, Maria Diaz R, Thompson J, Chong H, Melcher A, Vile R. 421. Killing of Normal Cells Combined with TLR Engagement and CD40 Ligation Generates Autoimmune T Cell Reactivity Sufficient To Treat Large Established Tumors Molecular Therapy. 13: S162. DOI: 10.1016/J.Ymthe.2006.08.486 |
0.513 |
|
| 2006 |
Maria Diaz R, Galivo F, Qiao J, Thompson J, Kottke T, Bell J, Barber G, Vile R. 56. The Efficacy of Replicating Virotherapy for Tumors Involves a Complex Equilibrium between Virus, Tumor and the Immune System Molecular Therapy. 13: S24. DOI: 10.1016/J.Ymthe.2006.08.071 |
0.644 |
|
| 2006 |
Ilett L, Errington F, Morgan R, Vile R, Selby P, Melcher A. Sa.125. Dendritic Cell Activation by Tumour Cell-Derived Exosomes Clinical Immunology. 119: S149-S150. DOI: 10.1016/J.Clim.2006.04.357 |
0.34 |
|
| 2005 |
Cole C, Qiao J, Kottke T, Diaz RM, Ahmed A, Sanchez-Perez L, Brunn G, Thompson J, Chester J, Vile RG. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nature Medicine. 11: 1073-81. PMID 16170322 DOI: 10.1038/Nm1297 |
0.559 |
|
| 2005 |
Riddle DS, Sanz L, Chong H, Thompson J, Vile RG. Tumor cell surface display of immunoglobulin heavy chain Fc by gene transfer as a means to mimic antibody therapy. Human Gene Therapy. 16: 830-44. PMID 16000065 DOI: 10.1089/Hum.2005.16.830 |
0.55 |
|
| 2005 |
Gough M, Crittenden M, Thanarajasingam U, Sanchez-Perez L, Thompson J, Jevremovic D, Vile R. Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 174: 5766-73. PMID 15843579 DOI: 10.4049/Jimmunol.174.9.5766 |
0.608 |
|
| 2005 |
Merrick A, Errington F, Milward K, O'Donnell D, Harrington K, Bateman A, Pandha H, Vile R, Morrison E, Selby P, Melcher A. Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. British Journal of Cancer. 92: 1450-8. PMID 15812550 DOI: 10.1038/Sj.Bjc.6602518 |
0.406 |
|
| 2005 |
Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Melcher A, Holmen S, Daniels G, Vile RG. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Research. 65: 2009-17. PMID 15753401 DOI: 10.1158/0008-5472.Can-04-3216 |
0.555 |
|
| 2005 |
Hatfield P, Merrick A, Harrington K, Vile R, Bateman A, Selby P, Melcher A. Radiation-induced cell death and dendritic cells: Potential for cancer immunotherapy? Clinical Oncology. 17: 1-11. PMID 15714922 DOI: 10.1016/J.Clon.2004.06.014 |
0.421 |
|
| 2005 |
Sanz L, Qiao J, Vile RG, Alvarez-Vallina L. Antibody engineering, virus retargeting and cellular immunotherapy: one ring to rule them all? Current Gene Therapy. 5: 63-70. PMID 15638711 DOI: 10.2174/1566523052997479 |
0.432 |
|
| 2005 |
Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ. Intratumoral immunotherapy: using the tumour against itself. Immunology. 114: 11-22. PMID 15606790 DOI: 10.1111/J.1365-2567.2004.02001.X |
0.436 |
|
| 2005 |
Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER, Vile R, Göke B, Morris JC, Spitzweg C. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Therapy. 12: 272-280. PMID 15510175 DOI: 10.1038/Sj.Gt.3302410 |
0.494 |
|
| 2005 |
Sanchez-Perez L, Gough M, Qiao J, Thanarajasingam U, Ahmed A, Diaz RM, Vile R. 804. HSVtk Mediated Immunostimulatory Tumor Cell Killing Enhances Adoptive T Cell Therapy in a B16 Melanoma Model Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.341 |
0.625 |
|
| 2005 |
Thanarajasingam U, Sanz L, Diaz RM, Thompson J, Gough M, Vile R. 802. Use of Chemokine Expression at a Tumor Site to Enhance Immune Cell Trafficking for Melanoma Therapy Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.339 |
0.616 |
|
| 2005 |
Qiao J, Moreno J, Kottke T, Forshaw M, Diaz RM, Vile R. 723. VSV-G Pseudotyped, Semi-Replication Competent MLV Retroviruses for Cancer Gene Therapy Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.263 |
0.562 |
|
| 2005 |
Lang S, Riddle D, Sanz L, Chong H, Thompson J, Vile R. 704. Tumor Cell Surface Display of the Immunoglobulin Heavy Chain Fc by Gene Transfer as a Means to Mimic Antibody Therapy Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.244 |
0.496 |
|
| 2005 |
Qiao J, Cole C, Kottke T, Diaz RM, Sanchez-Perez L, Brunn G, Thompson J, Vile R. 449. Tumor Targeted, Systemic Delivery of Therapeutic Viral Vectors Using Hitch Hiking on Antigen Specific T Cells Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.457 |
0.559 |
|
| 2005 |
Forshaw M, Cole C, Kottke T, Thompson J, Qiao J, Selby P, Melcher A, Vile R. 271. Interactions between Replicating Virotherapy and Tumor Growth in the Presence of an Intact Immune System Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.274 |
0.542 |
|
| 2005 |
Sanchez-Perez L, Daniels G, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Vile R. 267. Inflammatory Killing of Normal Cells To Treat Metastatic Tumors Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.270 |
0.595 |
|
| 2004 |
Bonnotte B, Crittenden M, Larmonier N, Gough M, Vile RG. MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. Journal of Immunology (Baltimore, Md. : 1950). 173: 4929-35. PMID 15470034 DOI: 10.4049/Jimmunol.173.8.4929 |
0.508 |
|
| 2004 |
Daniels GA, Sanchez-Perez L, Diaz RM, Kottke T, Thompson J, Lai M, Gough M, Karim M, Bushell A, Chong H, Melcher A, Harrington K, Vile RG. A simple method to cure established tumors by inflammatory killing of normal cells. Nature Biotechnology. 22: 1125-32. PMID 15300260 DOI: 10.1038/Nbt1007 |
0.54 |
|
| 2004 |
Qiao J, Diaz RM, Vile RG. Success for gene therapy: render unto Caesar that which is Caesar's. Genome Biology. 5: 237. PMID 15287968 DOI: 10.1186/Gb-2004-5-8-237 |
0.343 |
|
| 2004 |
Jevremovic D, Gulati R, Hennig I, Diaz RM, Cole C, Kleppe L, Cosset FL, Simari RD, Vile RG. Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors. American Journal of Physiology. Heart and Circulatory Physiology. 287: H494-500. PMID 15277193 DOI: 10.1152/Ajpheart.00064.2004 |
0.509 |
|
| 2004 |
Harrington KJ, Syrigos KN, Uster PS, Zetter A, Lewanski CR, Gullick WJ, Vile RG, Stewart JS. Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model. British Journal of Cancer. 91: 366-73. PMID 15199395 DOI: 10.1038/Sj.Bjc.6601958 |
0.33 |
|
| 2004 |
Gough MJ, Melcher AA, Crittenden MR, Sanchez-Perez L, Voellmy R, Vile RG. Induction of cell stress through gene transfer of an engineered heat shock transcription factor enhances tumor immunogenicity Gene Therapy. 11: 1099-1104. PMID 15103319 DOI: 10.1038/Sj.Gt.3302274 |
0.419 |
|
| 2004 |
Qiao J, Moreno J, Forshaw M, Diaz RM, Vile RG. 741. VSV-G Pseudotyped, MLV-Based, Semi-Replication-Competent Retroviruses for Cancer Gene Therapy Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.703 |
0.377 |
|
| 2004 |
Ahmed A, Qiao J, Moreno J, Vile RG. 451. A Novel Cell Cycle Dependent Conditionally Replicating Adenovirus Vector for Targeting a Broad-Spectrum of Cancer Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.401 |
0.469 |
|
| 2004 |
Daniels G, Sanchez-Perez L, Kottke T, Diaz RM, Thompson J, Lai M, Gough M, Karim M, Bushell A, Chong H, Melcher A, Harrington K, Vile RG. Intentional killing of normal nelanocytes by gene transfer generates curative anti melanoma immunity without obligate autoimmunity Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.306 |
0.583 |
|
| 2004 |
Sanchez-Perez LA, Gough M, Thompson J, Vile RG. 256. Importance of Temporal Control of HSVtk Gene Therapy in Combination with T Cell Based Therapies for Cancer Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.197 |
0.598 |
|
| 2004 |
Cole C, Diaz RM, Forshaw M, Kottke T, Thompson J, Gough M, Breakefield X, Sena-Esteves M, Qiao J, Vile RG. 23. T Cell Carriers for Gene Delivery to Tumors Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.05.046 |
0.56 |
|
| 2003 |
Gulati R, Jevremovic D, Peterson TE, Chatterjee S, Shah V, Vile RG, Simari RD. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circulation Research. 93: 1023-5. PMID 14605020 DOI: 10.1161/01.Res.0000105569.77539.21 |
0.303 |
|
| 2003 |
Crittenden M, Gough M, Harrington K, Olivier K, Thompson J, Vile RG. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Research. 63: 5505-12. PMID 14500387 |
0.48 |
|
| 2003 |
Phan V, Errington F, Cheong SC, Kottke T, Gough M, Altmann S, Brandenburger A, Emery S, Strome S, Bateman A, Bonnotte B, Melcher A, Vile R. A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nature Medicine. 9: 1215-9. PMID 12925849 DOI: 10.1038/Nm923 |
0.497 |
|
| 2003 |
Ahmed A, Jevremovic D, Suzuki K, Kottke T, Thompson J, Emery S, Harrington K, Bateman A, Vile R. Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene Therapy. 10: 1663-71. PMID 12923565 DOI: 10.1038/Sj.Gt.3302064 |
0.563 |
|
| 2003 |
Blanco B, Holliger P, Vile RG, Alvarez-Vallina L. Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. Journal of Immunology (Baltimore, Md. : 1950). 171: 1070-7. PMID 12847281 DOI: 10.4049/Jimmunol.171.2.1070 |
0.55 |
|
| 2003 |
Crittenden M, Gough M, Chester J, Kottke T, Thompson J, Ruchatz A, Clackson T, Cosset FL, Chong H, Diaz RM, Harrington K, Alvarez Vallina L, Vile R. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Research. 63: 3173-80. PMID 12810645 |
0.499 |
|
| 2003 |
Ahmed A, Thompson J, Emiliusen L, Murphy S, Beauchamp RD, Suzuki K, Alemany R, Harrington K, Vile RG. A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nature Biotechnology. 21: 771-7. PMID 12794639 DOI: 10.1038/Nbt835 |
0.443 |
|
| 2003 |
Fu X, Tao L, Jin A, Vile R, Brenner MK, Zhang X. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect Molecular Therapy. 7: 748-754. PMID 12788648 DOI: 10.1016/S1525-0016(03)00092-3 |
0.455 |
|
| 2003 |
Bonnotte B, Gough M, Phan V, Ahmed A, Chong H, Martin F, Vile RG. Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells. Cancer Research. 63: 2145-9. PMID 12727832 |
0.406 |
|
| 2002 |
Vile R, Ando D, Kirn D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Therapy. 9: 1062-1067. PMID 12522445 DOI: 10.1038/Sj.Cgt.7700548 |
0.306 |
|
| 2002 |
Cohen-Haguenauer O, Rosenthal F, Gänsbacher B, Bolhuis R, Dorsch-Häsler K, Eshhar Z, Gahrton G, Hokland P, Melani C, Rankin E, Thielemans K, Vile R, Zwierzina H, Cichutek K. Opinion paper on the current status of the regulation of gene therapy in Europe. Human Gene Therapy. 13: 2085-110. PMID 12490003 DOI: 10.1089/10430340260395938 |
0.33 |
|
| 2002 |
Kirkham LA, Bateman AR, Melcher AA, Vile RG, Fielding AK. Lack of specificity of cell-surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein. The Journal of Gene Medicine. 4: 592-600. PMID 12439851 DOI: 10.1002/Jgm.306 |
0.344 |
|
| 2002 |
Bateman AR, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ, Linardakis E, Riddle D, Dietz A, Lohse CM, Strome S, Peterson T, Simari R, Vile RG. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Research. 62: 6566-78. PMID 12438252 |
0.493 |
|
| 2002 |
Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K, Kennedy R, Errington F, Harrington KJ, Melcher A, Vile R. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Research. 62: 5495-504. PMID 12359759 |
0.48 |
|
| 2002 |
Harrington K, Alvarez-Vallina L, Crittenden M, Gough M, Chong H, Diaz RM, Vassaux G, Lemoine N, Vile R. Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Human Gene Therapy. 13: 1263-80. PMID 12162810 DOI: 10.1089/104303402760128504 |
0.569 |
|
| 2002 |
Melcher A, Bateman A, Harrington K, Ahmed A, Gough M, Vile R. Dendritic cells for the immunotherapy of cancer. Clinical Oncology (Royal College of Radiologists (Great Britain)). 14: 185-92. PMID 12109820 DOI: 10.1053/Clon.2001.0038 |
0.338 |
|
| 2002 |
Harrington KJ, Melcher AA, Bateman AR, Ahmed A, Vile RG. Cancer gene therapy: Part 2. Candidate transgenes and their clinical development. Clinical Oncology (Royal College of Radiologists (Great Britain)). 14: 148-69. PMID 12069125 DOI: 10.1053/Clon.2001.0004 |
0.343 |
|
| 2002 |
Murphy SJ, Chong H, Bell S, Diaz RM, Vile RG. Novel integrating adenoviral/retroviral hybrid vector for gene therapy. Human Gene Therapy. 13: 745-60. PMID 11936973 DOI: 10.1089/104303402317322302 |
0.364 |
|
| 2002 |
Strome SE, Voss S, Wilcox R, Wakefield TL, Tamada K, Flies D, Chapoval A, Lu J, Kasperbauer JL, Padley D, Vile R, Gastineau D, Wettstein P, Chen L. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Research. 62: 1884-9. PMID 11912169 |
0.44 |
|
| 2002 |
Harrington KJ, Bateman AR, Melcher AA, Ahmed A, Vile RG. Cancer gene therapy: Part 1. Vector development and regulation of gene expression. Clinical Oncology (Royal College of Radiologists (Great Britain)). 14: 3-16. PMID 11898782 DOI: 10.1053/Clon.2001.0002 |
0.311 |
|
| 2002 |
Chester J, Ruchatz A, Gough M, Crittenden M, Chong H, Cosset FL, Loïc-Cosset F, Diaz RM, Harrington K, Alvarez-Vallina L, Vile R. Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nature Biotechnology. 20: 256-63. PMID 11875426 DOI: 10.1038/Nbt0302-256 |
0.592 |
|
| 2002 |
Chong H, Ruchatz A, Clackson T, Rivera VM, Vile RG. A system for small-molecule control of conditionally replication-competent adenoviral vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 5: 195-203. PMID 11829527 DOI: 10.1006/Mthe.2002.0531 |
0.404 |
|
| 2001 |
Todryk S, Melcher A, Bottley G, Gough M, Vile R. Cell death associated with genetic prodrug activation therapy of colorectal cancer. Cancer Letters. 174: 25-33. PMID 11675149 DOI: 10.1016/S0304-3835(01)00679-6 |
0.442 |
|
| 2001 |
Harrington KJ, Lewanski C, Northcote AD, Whittaker J, Peters AM, Vile RG, Stewart JS. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. European Journal of Cancer (Oxford, England : 1990). 37: 2015-22. PMID 11597379 DOI: 10.1016/S0959-8049(01)00216-7 |
0.302 |
|
| 2001 |
Gough MJ, Melcher AA, Ahmed A, Crittenden MR, Riddle DS, Linardakis E, Ruchatz AN, Emiliusen LM, Vile RG. Macrophages orchestrate the immune response to tumor cell death Cancer Research. 61: 7240-7247. PMID 11585761 |
0.454 |
|
| 2001 |
Harrington KJ, Spitzweg C, Bateman AR, Morris JC, Vile RG. Gene therapy for prostate cancer: current status and future prospects. The Journal of Urology. 166: 1220-1233. PMID 11547047 DOI: 10.1016/S0022-5347(05)65742-4 |
0.383 |
|
| 2001 |
Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Vile RG, Peters AM, Stewart JS. The effect of irradiation on the biodistribution of radiolabeled pegylated liposomes. International Journal of Radiation Oncology, Biology, Physics. 50: 809-20. PMID 11395251 DOI: 10.1016/S0360-3016(01)01508-5 |
0.389 |
|
| 2001 |
Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, Poland GA, Fielding AK. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood. 97: 3746-54. PMID 11389012 DOI: 10.1182/Blood.V97.12.3746 |
0.502 |
|
| 2001 |
Galanis E, Vile RG, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors Critical Reviews in Oncology Hematology. 38: 177-192. PMID 11369253 DOI: 10.1016/S1040-8428(01)00103-2 |
0.424 |
|
| 2001 |
Galanis E, Bateman A, Johnson K, Diaz RM, James CD, Vile R, Russell SJ. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Human Gene Therapy. 12: 811-21. PMID 11339897 DOI: 10.1089/104303401750148766 |
0.458 |
|
| 2001 |
Harrington KJ, Rowlinson-Busza G, Uster PS, Vile RG, Peters AM, Stewart JS. Single-fraction irradiation has no effect on uptake of radiolabeled pegylated liposomes in a tumor xenograft model. International Journal of Radiation Oncology, Biology, Physics. 49: 1141-8. PMID 11240257 DOI: 10.1016/S0360-3016(00)01444-9 |
0.452 |
|
| 2001 |
Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 243-54. PMID 11234875 |
0.35 |
|
| 2000 |
Harrington KJ, Rowlinson-Busza G, Syrigos KN, Vile RG, Uster PS, Peters AM, Stewart JS. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 4939-49. PMID 11156255 |
0.381 |
|
| 2000 |
Diaz RM, Bateman A, Emiliusen L, Fielding A, Trono D, Russell SJ, Vile RG. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Therapy. 7: 1656-63. PMID 11083474 DOI: 10.1038/Sj.Gt.3301277 |
0.424 |
|
| 2000 |
Harrington KJ, Linardakis E, Vile RG. Transcriptional control: An essential component of cancer gene therapy strategies? Advanced Drug Delivery Reviews. 44: 167-184. PMID 11072113 DOI: 10.1016/S0169-409X(00)00093-4 |
0.375 |
|
| 2000 |
Melero I, Vile RG, Colombo MP. Feeding dendritic cells with tumor antigens: Self-service buffet or a la carte? Gene Therapy. 7: 1167-1170. PMID 10918484 DOI: 10.1038/Sj.Gt.3301234 |
0.523 |
|
| 2000 |
Vile RG. Cancer gene therapy--new approaches to tumour cell killing. Journal of Gene Medicine. 2: 141-143. PMID 10809148 DOI: 10.1002/(Sici)1521-2254(200003/04)2:2<141::Aid-Jgm93>3.0.Co;2-2 |
0.356 |
|
| 2000 |
Bateman A, Bullough F, Murphy S, Emiliusen L, Lavillette D, Cosset FL, Cattaneo R, Russell SJ, Vile RG. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth Cancer Research. 60: 1492-1497. PMID 10749110 |
0.444 |
|
| 2000 |
Todryk SM, Melcher AA, Dalgleish AG, Vile RG. Heat shock proteins refine the danger theory Immunology. 99: 334-337. PMID 10712661 DOI: 10.1046/J.1365-2567.2000.00002.X |
0.357 |
|
| 2000 |
Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: hard lessons and new courses. Gene Therapy. 7: 2-8. PMID 10680008 DOI: 10.1038/Sj.Gt.3301084 |
0.365 |
|
| 1999 |
Melcher A, Gough M, Todryk S, Vile R. Apoptosis or necrosis for tumor immunotherapy: what's in a name? Journal of Molecular Medicine. 77: 824-833. PMID 10682318 DOI: 10.1007/S001099900066 |
0.547 |
|
| 1999 |
Todryk S, McLean C, Ali S, Entwistle C, Boursnell M, Rees R, Vile R. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer. Human Gene Therapy. 10: 2757-2768. PMID 10584922 DOI: 10.1089/10430349950016492 |
0.555 |
|
| 1999 |
Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppacciaro A, Vile RG. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake Journal of Immunology. 163: 1398-1408. PMID 10415040 |
0.434 |
|
| 1999 |
Melcher A, Murphy S, Vile R. Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors. Human Gene Therapy. 10: 1431-1442. PMID 10395369 DOI: 10.1089/10430349950017770 |
0.36 |
|
| 1999 |
Melcher A, Todryk S, Bateman A, Chong H, Lemoine NR, Vile RG. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Research. 59: 2802-5. PMID 10383135 |
0.423 |
|
| 1998 |
Todryk SM, Chong H, Vile RG, Pandha H, Lemoine NR. Can immunotherapy by gene transfer tip the balance against colorectal cancer? Gut. 43: 445-9. PMID 9824562 DOI: 10.1136/Gut.43.4.445 |
0.405 |
|
| 1998 |
Diaz RM, Todryk S, Chong H, Hart IR, Sikora K, Dorudi S, Vile RG. Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer. Gene Therapy. 5: 869-79. PMID 9813657 DOI: 10.1038/Sj.Gt.3300690 |
0.348 |
|
| 1998 |
Chong H, Hutchinson G, Hart IR, Vile RG. Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumours British Journal of Cancer. 78: 1043-1050. PMID 9792148 DOI: 10.1038/Bjc.1998.625 |
0.373 |
|
| 1998 |
Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression Nature Medicine. 4: 581-587. PMID 9585232 DOI: 10.1038/Nm0598-581 |
0.415 |
|
| 1997 |
Castleden SA, Chong H, Garcia-Ribas I, Melcher AA, Hutchinson G, Roberts B, Hart IR, Vile RG. A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model Human Gene Therapy. 8: 2087-2102. PMID 9414257 |
0.398 |
|
| 1997 |
Vile RG, Diaz RM, Castleden S, Chong H. Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells. Biochemical Society Transactions. 25: 717-22. PMID 9191190 |
0.326 |
|
| 1997 |
Vile RG, Castleden S, Marshall J, Camplejohn R, Uptov C, Chong H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression International Journal of Cancer. 71: 267-274. PMID 9139853 DOI: 10.1002/(Sici)1097-0215(19970410)71:2<267::Aid-Ijc23>3.0.Co;2-D |
0.413 |
|
| 1996 |
Chong H, Hutchinson G, Hart IR, Vile RG. Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity Human Gene Therapy. 7: 1771-1779. PMID 8886848 DOI: 10.1089/Hum.1996.7.14-1771 |
0.566 |
|
| 1996 |
Vile RG, Tuszynski A, Castleden S. Retroviral vectors - From Laboratory Tools to Molecular Medicines Molecular Biotechnology. 5: 139-158. PMID 8734426 DOI: 10.1007/Bf02789062 |
0.326 |
|
| 1995 |
Vile RG, Russell SJ. Retroviruses as vectors British Medical Bulletin. 51: 12-30. PMID 7767638 DOI: 10.1093/Oxfordjournals.Bmb.A072941 |
0.363 |
|
| 1995 |
Castleden S, Tuszynski A, Chong H, Hart I, Vile R. In vivo gene therapy of metastatic melanoma using the HSVtk gene by co-activation of anti-tumour immunity European Journal of Cancer. 31. DOI: 10.1016/0959-8049(95)99894-6 |
0.36 |
|
| 1994 |
Hart IR, Vile RG. Targeted therapy for malignant melanoma Current Opinion in Oncology. 6: 221-225. PMID 8011700 DOI: 10.1097/00001622-199403000-00016 |
0.422 |
|
| 1994 |
Vile RG, Nelson A, Castleden S, Chong H, Hart IR. Systemic Gene Therapy of Murine Melanoma Using Tissue Specific Expression of the HSVtk Gene Involves an Immune Component Cancer Research. 54: 6228-6234. PMID 7954471 |
0.408 |
|
| 1994 |
Vile RG. Tumor-specific gene expression Seminars in Cancer Biology. 5: 429-436. PMID 7703442 |
0.408 |
|
| 1993 |
Vile RG, Hart IR. In Vitro and in Vivo Targeting of Gene Expression to Melanoma Cells Cancer Research. 53: 962-967. PMID 8439971 |
0.421 |
|
| 1993 |
Vile RG, Hart IR. Use of Tissue-specific Expression of the Herpes Simplex Virus Thymidine Kinase Gene to Inhibit Growth of Established Murine Melanomas following Direct Intratumoral Injection of DNA Cancer Research. 53: 3860-3864. PMID 8395331 |
0.422 |
|
| 1992 |
Takeuchi Y, Simpson G, Vile RG, Weiss RA, Collins MKL. Retroviral pseudotypes produced by rescue of a moloney murine leukemia virus vector by C-type, but not D-type, retroviruses Virology. 186: 792-794. PMID 1733113 DOI: 10.1016/0042-6822(92)90049-U |
0.56 |
|
| 1992 |
Takeuchi Y, Vile RG, Simpson G, O'Hara B, Collins MKL, Weiss RA. Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus Journal of Virology. 66: 1219-1222. PMID 1309898 DOI: 10.1128/Jvi.66.2.1219-1222.1992 |
0.541 |
|
| 1991 |
Vile RG, Weiss RA. Virus receptors as permeases Nature. 352: 666-667. PMID 1876178 DOI: 10.1038/352666A0 |
0.412 |
|
| 1991 |
Vile RG, Schulz TF, Danos OF, Collins MKL, Weiss RA. A murine cell line producing HTLV-I pseudotype virions carrying a selectable marker gene Virology. 180: 420-424. PMID 1845835 DOI: 10.1016/0042-6822(91)90050-L |
0.5 |
|
| Show low-probability matches. |